Literature DB >> 18429050

Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population.

Victor R Gordeuk1, David M Reboussin, Christine E McLaren, James C Barton, Ronald T Acton, Gordon D McLaren, Emily L Harris, Jacob A Reiss, Paul C Adams, Mark Speechley, Pradyumna D Phatak, Phyliss Sholinsky, John H Eckfeldt, Wen-Pin Chen, Leah Passmore, Fitzroy W Dawkins.   

Abstract

How often elevated serum ferritin in primary-care patients reflects increased iron stores (normally 0.8 g in men, 0.4 g in women) is not known. The Hereditary Hemochromatosis and Iron Overload Screening (HEIRS) study screened 101,168 primary-care participants (44% Caucasians, 27% African-Americans, 14% Asians/Pacific Islanders, 13% Hispanics, 2% others). Follow-up clinical evaluation was performed in 302 of 333 HFE C282Y homozygotes regardless of iron measures and 1,375 of 1,920 nonhomozygotes with serum ferritin >300 microg/L (men), >200 microg/L (women) and transferrin saturation >50% (men), >45% (women). Quantitative phlebotomy was conducted in 122 of 175 C282Y homozygotes and 122 of 1,102 nonhomozygotes with non-transfusional serum ferritin elevation at evaluation. The estimated prevalence in the Caucasian population of C282Y homozygotes with serum ferritin >900 microg/L at evaluation was 20 per 10,000 men and 4 per 10,000 women; this constellation was predictive of iron stores >4 g in men and >2 g in women. The estimated prevalence per 10,000 of non-C282Y homozygotes with serum ferritin >900 microg/L at evaluation was 7 among Caucasians, 13 among Hispanics, 20 among African Americans, and 38 among Asians and Pacific Islanders, and this constellation was predictive of iron stores >2 g but <4 g. In conclusion, serum ferritin >900 microg/L after initial elevations of both serum ferritin and transferrin saturation is predictive of mildly increased iron stores in multiple ethnic populations regardless of HFE genotype. Serum ferritin >900 microg/L in male C282Y homozygotes is predictive of moderately increased iron stores. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18429050      PMCID: PMC3773165          DOI: 10.1002/ajh.21179

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  34 in total

1.  Countries of ancestry reported by hemochromatosis probands and control subjects in central Alabama.

Authors:  Ellen H Barton; James C Barton; William W Hollowell; Ronald T Acton
Journal:  Ethn Dis       Date:  2004       Impact factor: 1.847

2.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

3.  Measurements of iron status in patients with chronic hepatitis.

Authors:  A M Di Bisceglie; C A Axiotis; J H Hoofnagle; B R Bacon
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis.

Authors:  P C Adams
Journal:  Am J Hematol       Date:  1998-05       Impact factor: 10.047

5.  Ferritin in body fluids.

Authors:  C W Aungst
Journal:  J Lab Clin Med       Date:  1968-03

6.  Iron stores in normal men and male blood donors. As measured by desferrioxamine and quantitative phlebotomy.

Authors:  K S Olsson
Journal:  Acta Med Scand       Date:  1972-11

7.  The effect of erythroid hyperplasia on iron balance.

Authors:  P Pootrakul; K Kitcharoen; P Yansukon; P Wasi; S Fucharoen; P Charoenlarp; G Brittenham; M J Pippard; C A Finch
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

8.  Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.

Authors:  Bret L Hicken; Diane C Tucker; James C Barton
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

9.  Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles.

Authors:  D O Stram; J H Hankin; L R Wilkens; M C Pike; K R Monroe; S Park; B E Henderson; A M Nomura; M E Earle; F S Nagamine; L N Kolonel
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

10.  Serum ferritin in patients with iron overload and with acute and chronic liver diseases.

Authors:  J Prieto; M Barry; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

View more
  14 in total

1.  Elevated transferrin saturation, health-related quality of life and telomere length.

Authors:  Arch G Mainous; Robert U Wright; Mary M Hulihan; Waleed O Twal; Christine E McLaren; Vanessa A Diaz; Gordon D McLaren; W Scott Argraves; Althea M Grant
Journal:  Biometals       Date:  2013-12-15       Impact factor: 2.949

2.  Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS study.

Authors:  Ronald T Acton; J Clayborn Barton; James C Barton
Journal:  Metab Syndr Relat Disord       Date:  2014-11-25       Impact factor: 1.894

3.  Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.

Authors:  Christine E McLaren; Mary J Emond; V Nathan Subramaniam; Pradyumna D Phatak; James C Barton; Paul C Adams; Justin B Goh; Cameron J McDonald; Lawrie W Powell; Lyle C Gurrin; Katrina J Allen; Deborah A Nickerson; Tin Louie; Grant A Ramm; Gregory J Anderson; Gordon D McLaren
Journal:  Hepatology       Date:  2015-03-18       Impact factor: 17.425

4.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

5.  Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.

Authors:  Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2020-04-21       Impact factor: 10.047

Review 6.  Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice.

Authors:  Kristina M Utzschneider; Kris V Kowdley
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

Review 7.  Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study.

Authors:  Paul Adams; James C Barton; Gordon D McLaren; Ronald T Acton; Mark Speechley; Christine E McLaren; David M Reboussin; Catherine Leiendecker-Foster; Emily L Harris; Beverly M Snively; Thomas Vogt; Phyliss Sholinsky; Elizabeth Thomson; Fitzroy W Dawkins; Victor R Gordeuk; John H Eckfeldt
Journal:  Can J Gastroenterol       Date:  2009-11       Impact factor: 3.522

8.  Ethnic and genetic factors of iron status in women of reproductive age.

Authors:  Victor R Gordeuk; Patsy M Brannon
Journal:  Am J Clin Nutr       Date:  2017-10-25       Impact factor: 7.045

9.  A comparison between whites and blacks with severe multi-organ iron overload identified in 16,152 autopsies.

Authors:  James C Barton; Ronald T Acton; Laura E Anderson; C Bruce Alexander
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-21       Impact factor: 11.382

Review 10.  Hyperferritinemia-A Clinical Overview.

Authors:  Miriam Sandnes; Rune J Ulvik; Marta Vorland; Håkon Reikvam
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.